Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates

被引：18

作者：

Fu, Zhiwen ^{[1
,2
]}

Gao, Chen ^{[1
,2
]}

Wu, Tingting ^{[1
,2
]}

Wang, Lulu ^{[1
,2
]}

Li, Shijun ^{[1
,2
]}

Zhang, Yu ^{[1
,2
]}

Shi, Chen ^{[1
,2
]}

机构：

[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430000, Peoples R China

[2] Hubei Prov Clin Res Ctr Precis Med Crit Illness, Wuhan 430000, Peoples R China

来源：

ISCIENCE | 2023年 / 26卷 / 10期

基金：

中国国家自然科学基金;

关键词：

ACETYL-L-CARNITINE; BRENTUXIMAB VEDOTIN SGN-35; TAXANE-INDUCED NEUROPATHY; OPEN-LABEL; OBJECTIVE RESPONSES; POLATUZUMAB VEDOTIN; HODGKIN-LYMPHOMA; STAGE-III; CHEMOTHERAPY; NEUROTOXICITY;

D O I：

10.1016/j.isci.2023.107778

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Since the successful approval of gemtuzumab ozogamicin, antibody-drug conjugates (ADCs) have emerged as a pivotal category of targeted therapies for cancer. Among these ADCs, the use of monomethyl auristatin E (MMAE) as a payload is prevalent in the development of ADC drugs, which has significantly improved overall therapeutic efficacy against various malignancies. However, increasing clinical observations have raised concerns regarding the potential nervous system toxicity associated with MMAE-based ADCs. Specifically, a higher incidence of peripheral neuropathy has been reported in ADCs incorporating MMAE as payloads. Considering the increasing global use of MMAE-based ADCs, it is imperative to provide an inclusive overview of diagnostic and management strategies for this adverse event. In this review, we examine current information and what future research directions are required to better understand and manage this type of clinical challenge.

引用

页数：13

共 126 条

[1]

Akaiwa M, 2020, CHEM PHARM BULL, V68, P201, DOI 10.1248/cpb.c19-00853

[2] Sensory neuron-associated macrophages as novel modulators of neuropathic pain [J].